Emcure Pharma Makes A Stellar Debut, Lists At 31% Premium To Issue Price | CNBC TV18

Emcure Pharma IPO Listing: Shares Debut At Nearly 32% Premium Over IPO Price | N18S | CNBC TV18Подробнее

#sharktankindia Fame Namita Thapar's Emcure Pharma lists at 31% premium on NSE | New ListingПодробнее

Emcure Pharma Lists At 31% Premium Over IPO Price, Management To Focus On Emerging MarketsПодробнее

Emcure Pharma Gains After Kotak Instl Equities Upgrades It To Buy With Target Of ₹1,680 | CNBC TV18Подробнее

Emcure Pharma Gains After Jefferies Initiates Coverage With Buy Rating & Target Price Of ₹1,600Подробнее

Kotak Instl Equities Initiates Coverage On Emcure Pharma With 'Add' Rating; Target Price Of 1,655/ShПодробнее

Neumora's depression drug fails trial, sinking sharesПодробнее

Namita Thapar | Shark Tank India | Emcure Pharmaceutical | #sharktankindia #sharktank #stockmarketПодробнее

What's the BEST Cold and Flu Product for You? Pharmacist ReviewsПодробнее

Emcure presents AICOG tvПодробнее

Emcure EmistaПодробнее

It has never been easier to shop for the best deals and health care is no exceptionПодробнее